文献速递主动脉疾病

EVAR术后严重失败模式具有器械特异性

Serious Failure Modes After EVAR Are Device Specific.
PubMed 文献 · J Endovasc Ther · 2024-05-11

该研究回顾性分析了2002至2019年间因I型和III型内漏接受开放转换或主要血管内再干预的229例EVAR术后患者,评估不同器械的严重失败模式。结果显示I型内漏是最常见的再干预指征,但AFX器械更常表现为III型内漏,Ancure器械更常表现为IB型内漏,近端迁移在AneuRx器械中常见。作者认为了解各器械的差异失败模式有助于指导监测和随访。

要点

  • EVAR术后严重失败模式因内植物器械而异。
  • AFX器械更常表现为III型内漏,Ancure器械更常表现为IB型内漏。
  • I型内漏是除AFX和Ancure外所有器械再干预的最常见指征。

核心结论

  • EVAR术后严重失败模式在不同内植物之间不同,且在整个随访期间均可发生。
  • 了解各器械的差异失败模式有助于指导监测研究和随访计划的针对性询问,即使对于已停用器械也是如此,并有助于比较不同系列和估计EVAR失败率。

研究设计与样本

  • 回顾性综述了2002年至2019年间在本机构因I型/III型内漏接受开放转换或主要血管内干预(再衬里、袖套/分支延伸、平行支架)的既往EVAR患者。
  • 共纳入229例患者(194例男性),器械植入时间为1997年至2019年,其中90例开放转换,139例主要血管内干预。

主要发现

  • 再干预时平均年龄为78±8.5岁,135例(59%)在本机构植入,93例(41%)为转诊。
  • 再干预中位时间为4年,四分位距(IQR)为2.2-6.6年。
  • 42/229例(18%)表现为动脉瘤破裂,20/229例(9%)有症状,其余为无症状影像学发现。
  • I型内漏分布:1A型146/229例(63.8%,其中72例近端迁移),1B型46/229例(20.1%),IIIA型37/229例(16.6%),IIIB型15/229例(6.5%),持续瘤囊增大但无内漏影像学证据者6/229例(2.6%)。
  • 除AFX和Ancure器械外,1A型内漏是所有器械再干预的最常见指征,近端迁移在AneuRx器械中常见;AFX器械更常表现为III型内漏,Ancure器械更常表现为1B型内漏。

临床怎么用

  • EVAR术后监测对修复的长期成功至关重要,了解每种可用移植物的差异失败模式对于这些内植物的纵向评估很重要。
  • 同样重要的是了解已不在市场上但仍在随访的 legacy 内植物的失败模式,以便量身定制监测方案和必要时的最终修复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Type I and III endoleaks following endovascular aneurysm repair (EVAR) can lead to catastrophic events that require major re-interventions. We reviewed our experience with aortic endograft re-interventions for type I and III endoleaks and other serious failures among different devices. METHODS: We retrospectively reviewed patients with a prior EVAR who underwent open conversion (OC) or major endovascular intervention (MEI) (re-lining, cuff/limb extension, parallel graft) for type I/III endoleaks at our institution from 2002 to 2019. Baseline characteristics, procedural details, re-interventions, and outcomes were collected. RESULTS: A total of 229 patients (194 men) underwent re-interventions for type I and III endoleaks after EVAR (90 OC, 139 MEI) for devices implanted between 1997 and 2019. Average age at re-intervention was 78±8.5 years. A total of 135 (59%) were implanted at our institution, whereas 93 (41%) were referred. Median time to re-intervention was 4 years with 25% to 75% interquartile range (IQR) of 2.2-6.6 years. There was no significant difference in baseline demographics or type of re-interventions (OC/MEI) between device types. 42/229 (18%) presented with ruptured aneurysms, 20/229 (9%) were symptomatic, whereas the rest presented with asymptomatic radiographic findings. Type 1A endoleak was present in 146/229 (63.8%-72 with proximal migration), type IB in 46/229 (20.1%), type IIIA in 37/229 (16.6%), type IIIB in 15/229 (6.5%), and persistent aneurysm sac growth with no radiographic evidence of an endoleak in 6/229 (2.6%). Devices included most commercial products: AFX, Excluder, AneuRx, Ancure, Endurant, and Zenith. A smaller number of investigational devices accounted for the rest. Type 1A endoleak was the most common indication for re-intervention among all devices except for AFX and ancure devices, proximal migration was a frequent presentation with AneuRx. AFX devices more frequently presented with a type III and ancure devices more frequently presented with a type IB endoleak. CONCLUSIONS: Serious failure modes after EVAR differ between endografts and occur throughout the follow-up period. This is important to guide targeted interrogation of surveillance studies and follow-up schedules, even for discontinued devices, as well as comparisons between various series and estimation of EVAR failure rates.Clinical ImpactSurveillance after EVAR is critical for long term success of the repair, understanding of the differential modes of failure of every graft available is important in the longitudinal evaluation of these endografts. Equally important is the understanding of the modes of failure of legacy endografts that are no longer on the market but still being followed, in order to be able to tailor a surveillance regiemn and the evntual repair if needed.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Abdul-Malak OM, Cherfan P, Liang N, et al. Serious Failure Modes After EVAR Are Device Specific. J Endovasc Ther. 2024. PMID: 38733297. doi:10.1177/15266028241248345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。